CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Research methodology
  1.3.1 Secondary research
  1.3.2 Primary research
  1.3.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
  3.2.1 Top investment pockets
  3.2.2 Top winning strategies
3.3 Porter¡¯s five forces analysis
  3.3.1 Bargaining power of suppliers
  3.3.2 Bargaining power of buyers
  3.3.3 Threat of new entrants
  3.3.4 Intensity of rivalry
  3.3.5 Threat of substitutes
3.4 Market share analysis, 2015
3.5 Market dynamics
  3.5.1 Drivers
    3.5.1.1 Ageing population and increasing incidence of neurological diseases
    3.5.1.2 Rise in the number of migraine and epilepsy patients and increase of neurostimulators in the treatment of depression and sleep apnea
    3.5.1.3 Increasing focus of leading companies in the neurostimulation segment
    3.5.1.4 New device approvals and increased clinical evidence of effectiveness
  3.5.2 Restraints
    3.5.2.1 Lack of skilled professionals
    3.5.2.2 High cost and lack of reimbursement
  3.5.3 Opportunities
    3.5.3.1 Rising healthcare expenditure in developing countries
    3.5.3.2 Use of neurostimulators for new indications
    3.5.3.3 Rising patient awareness about nuerostimulators

CHAPTER 4 WORLD NEUROMODULATION MARKET, BY TECHNOLOGY
4.1 OVERVIEW
  4.1.1 Market size and forecast
4.2 INTERNAL NEUROMODULATION
  4.2.1 Key market trends
  4.2.2 Key growth factors and opportunities
  4.2.3 Market size and forecast
  4.2.4 Deep brain stimulation
    4.2.4.1 Market size and forecast
  4.2.5 Sacral nerve stimulation
    4.2.5.1 Market size and forecast
  4.2.6 Spinal cord stimulation
    4.2.6.1 Market size and forecast
  4.2.7 Vagus nerve stimulation
    4.2.7.1 Market size and forecast
  4.2.8 Other neuromodulation
    4.2.8.1 Market size and forecast
4.3 External Neuromodulation
  4.3.1 Key market trends
  4.3.2 Key growth factors and opportunities
  4.3.3 Market size and forecast
  4.3.4 Transcutaneous electrical nerve stimulation
    4.3.4.1 Market size and forecast
  4.3.5 Transcranial magnetic stimulation
    4.3.5.1 Market size and forecast

CHAPTER 5 WORLD NEUROMODULATION MARKET, BY APPLICATION
5.1 Overview
  5.1.1 Market size and forecast
  5.1.2 Failed back syndrome
    5.1.2.1 Market size and forecast
  5.1.3 Chronic pain
    5.1.3.1 Market size and forecast
  5.1.4 Epilepsy
    5.1.4.1 Market size and forecast
  5.1.5 Essential tremor
    5.1.5.1 Market size and forecast
  5.1.6 Urinary and fecal incontinence
    5.1.6.1 Market size and forecast
  5.1.7 Depression
    5.1.7.1 Market size and forecast
  5.1.8 Dystonia
    5.1.8.1 Market size and forecast
  5.1.9 Gastroparesis
    5.1.9.1 Market size and forecast
  5.1.10 Parkinson's disease
    5.1.10.1 Market size and forecast
  5.1.11 Migraine
    5.1.11.1 Market size and forecast
  5.1.12 Obsessive-compulsive disorder
    5.1.12.1 Market size and forecast
  5.1.13 Other applications
    5.1.13.1 Market size and forecast

CHAPTER 6 WORLD NEUROMODULATION MARKET, BY BIOMATERIAL
6.1 Overview
  6.1.1 Market size and forecast
  6.1.2 Ceramics biomaterials
    6.1.2.1 Market size and forecast
  6.1.3 Metallic biomaterials
    6.1.3.1 Market size and forecast
  6.1.4 Polymeric biomaterials
    6.1.4.1 Market size and forecast

CHAPTER 7 WORLD NEUROMODULATION MARKET, BY GEOGRAPHY
7.1 Overview
  7.1.1 Market size and forecast
7.2 North America
  7.2.1 Key market trends
  7.2.2 Key growth factors and opportunities
  7.2.1 Market size and forecast
    7.2.1.1 U.S. market size and forecast
    7.2.1.2 Canada market size and forecast
    7.2.1.3 Mexico market size and forecast
7.3 Europe
  7.3.1 Key market trends
  7.3.2 Key growth factors and opportunities
  7.3.1 Market size and forecast
    7.3.1.1 Germany market size and forecast
    7.3.1.2 France market size and forecast
    7.3.1.3 U.K. market size and forecast
    7.3.1.4 Italy market size and forecast
    7.3.1.5 Spain market size and forecast
    7.3.1.6 Rest of europe market size and forecast
7.4 Asia-Pacific
  7.4.1 Key market trends
  7.4.2 Key growth factors and opportunities
  7.4.1 Market size and forecast
    7.4.1.1 Japan market size and forecast
    7.4.1.2 China market size and forecast
    7.4.1.3 India market size and forecast
    7.4.1.4 South Korea market size and forecast
    7.4.1.5 Malaysia market size and forecast
    7.4.1.6 Rest of Asia-Pacific market size and forecast
7.5 LAMEA
  7.5.1 Key market trends
  7.5.2 Key growth factors and opportunities
  7.5.1 Market size and forecast
    7.5.1.1 Brazil market size and forecast
    7.5.1.2 Israel market size and forecast
    7.5.1.3 Saudi Arabia market size and forecast
    7.5.1.4 South Africa market size and forecast
    7.5.1.5 Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES
8.1 ALEVA NEUROTHERAPEUTICS SA
  8.1.1 Company overview
  8.1.2 Company snapshot
  8.1.3 Operating business segments
  8.1.4 Key strategic moves & developments
8.2 BioControl Medical
  8.2.1 Company overview
  8.2.2 Company snapshot
  8.2.3 Operating business segments
  8.2.4 Key strategic moves & developments
8.3 Bioness Inc.
  8.3.1 Company overview
  8.3.2 Company snapshot
  8.3.3 Operating business segments
  8.3.4 Key strategic moves & developments
8.4 Boston Scientific Corporation
  8.4.1 Company overview
  8.4.2 Company snapshot
  8.4.3 Operating business segments
  8.4.4 Business performance
  8.4.5 Key strategic moves & developments
8.5 EnteroMedics Inc.
  8.5.1 Company overview
  8.5.2 Company snapshot
  8.5.3 Operating business segments
  8.5.4 Business performance
  8.5.5 Key strategic moves & developments
8.6 LivaNova PLC
  8.6.1 Company overview
  8.6.2 Company snapshot
  8.6.3 Operating business segments
  8.6.4 Business performance
  8.6.5 Key strategic moves & developments
8.7 Medtronic plc
  8.7.1 Company overview
  8.7.2 Company snapshot
  8.7.3 Operating business segments
  8.7.4 Business performance
  8.7.5 Key strategic moves & developments
8.8 NeuroPace, Inc.
  8.8.1 Company overview
  8.8.2 Company snapshot
  8.8.3 Operating business segments
  8.8.4 Key strategic moves & developments
8.9 Nevro Corporation
  8.9.1 Company overview
  8.9.2 Company snapshot
  8.9.3 Operating business segments
  8.9.4 Business performance
  8.9.5 Key strategic moves & developments
8.10 St. Jude Medical, Inc.
  8.10.1 Company overview
  8.10.2 Company snapshot
  8.10.3 Operating business segments
  8.10.4 Business performance
  8.10.5 Key strategic moves & developments

LIST OF TABLES
TABLE 1 WORLD NEUROMODULATION MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 2 INTERNAL NEUROMODULATION MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 3 EXTERNAL NEUROMODULATION MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 4 WORLD NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 5 NEUROMODULATION MARKET FOR FAILED BACK SYNDROME, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 6 NEUROMODULATION MARKET FOR CHRONIC PAIN, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 7 NEUROMODULATION MARKET FOR EPILEPSY, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8 NEUROMODULATION MARKET FOR ESSENTIAL TREMOR, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 9 NEUROMODULATION MARKET FOR URINARY AND FECAL INCONTINENCE, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 10 NEUROMODULATION MARKET FOR DEPRESSION, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 11 NEUROMODULATION MARKET FOR DYSTONIA, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12 NEUROMODULATION MARKET FOR GASTROPARESIS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13 NEUROMODULATION MARKET FOR PARKINSON¡¯S DISEASE, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 14 NEUROMODULATION MARKET FOR MIGRAINE, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15 NEUROMODULATION MARKET FOR OBSESSIVE-COMPULSIVE DISORDER, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 16 NEUROMODULATION MARKET FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17 WORLD NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
TABLE 18 NEUROMODULATION MARKET FOR CERAMIC BIOMATERIALS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 19 NEUROMODULATION MARKET FOR METALLIC BIOMATERIALS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 20 NEUROMODULATION MARKET FOR POLYMERIC BIOMATERIALS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 21 NEUROMODULATION MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 22 NORTH AMERICA NEUROMODULATION MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 23 NORTH AMERICA NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 24 NORTH AMERICA NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
TABLE 25 EUROPE NEUROMODULATION MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 26 EUROPE NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 27 EUROPE NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
TABLE 28 ASIA-PACIFIC NEUROMODULATION MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 29 ASIA-PACIFIC NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 30 ASIA-PACIFIC NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
TABLE 31 LAMEA NEUROMODULATION MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 32 LAMEA NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 33 LAMEA NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
TABLE 34 ALEVA: COMPANY SNAPSHOT
TABLE 35 ALEVA: PRODUCT CATEGORIES
TABLE 36 BIOCONTROL MEDICAL: COMPANY SNAPSHOT
TABLE 37 BIOCONTRL MEDICAL: PRODUCT CATEGORIES
TABLE 38 BIONESS: COMPANY SNAPSHOT
TABLE 39 BIONESS: PRODUCT CATEGORIES
TABLE 40 BOSTON SCIENTIFIC: COMPANY SNAPSHOT
TABLE 41 BOSTON SCIENTIFIC: PRODUCT CATEGORIES
TABLE 42 ENTEROMEDICSINC: COMPANY SNAPSHOT
TABLE 43 ENTEROMEDICSINC: PRODUCT CATEGORIES
TABLE 44 LIVANOVA: COMPANY SNAPSHOT
TABLE 45 LIVANOVA: PRODUCT CATEGORIES
TABLE 46 MEDTRONIC: COMPANY SNAPSHOT
TABLE 47 MEDTRONIC: OPERATING SEGMENTS
TABLE 48 NEUROPACE: COMPANY SNAPSHOT
TABLE 49 NEVRO: COMPANY SNAPSHOT
TABLE 50 NEVRO: PRODUCT CATEGORIES
TABLE 51 ST. JUDE MEDICAL: COMPANY SNAPSHOT
TABLE 52 ST. JUDE MEDICAL: PRODUCT CATEGORIES

LIST OF FIGURES
FIG. 1 TOP INVESTMENT POCKETS IN WORLD NEUROMODULATION MARKET
FIG. 2 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014–2016)
FIG. 3 TOP WINNING STRATEGIES: NATURE AND TYPE
FIG. 4 PORTER¡¯S FIVE FORCES ANALYSIS
FIG. 5 MARKET SHARE ANALYSIS, 2015
FIG. 6 U.S. NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 7 CANADA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 8 MEXICO NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 9 GERMANY NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 10 FRANCE NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 11 U.K. NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 12 ITALY NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 13 SPAIN NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 14 REST OF EUROPE NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 15 JAPAN NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 16 CHINA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 17 INDIA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 18 SOUTH KOREA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 19 MALAYSIA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 20 REST OF ASIA-PACIFIC NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 21 BRAZIL NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 22 ISRAEL NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 23 SAUDI ARABIA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 24 SOUTH AFRICA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 25 REST OF LAMEA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 26 BOSTON SCIENTIFIC: REVENUE, 2013–2015 ($MILLION)
FIG. 27 BOSTON SCIENTIFIC: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 28 BOSTON SCIENTIFIC: REVENUE, BY SUB SEGMENT, 2015 (%)
FIG. 29 BOSTON SCIENTIFIC: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 30 LIVANOVA: REVENUE, 2013–2015 ($MILLION)
FIG. 31 LIVANOVA: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 32 LIVANOVA: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 33 LIVANOVA: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 34 MEDTRONIC: REVENUE, 2014–2016 ($MILLION)
FIG. 35 MEDTRONIC: REVENUE, BY SEGMENT, 2016 (%)
FIG. 36 MEDTRONIC: CARDIAC AND VASCULAR GROUP REVENUE, BY SUBSEGMENT, 2016 (%)
FIG. 37 MEDTRONIC: REVENUE, BY GEOGRAPHY, 2016 (%)
FIG. 38 NEVRO: REVENUE, 2013–2015 ($MILLION)
FIG. 39 NEVRO: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 40 ST. JUDE MEDICAL: REVENUE, 2013–2015 ($MILLION)
FIG. 41 ST. JUDE MEDICAL: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 42 ST. JUDE MEDICAL: REVENUE, BY GEOGRAPHY, 2015 (%)

Title: Neuromodulation Devices Market by Technology (Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Spinal Cord Stimulation), Application (Chronic Pain Management, Failed back syndrome, Epilepsy, Tremor, Incontinence, Depression, Dystonia, Gastroparesis, Parkinsons disease, Obsessive-Compulsive Disorder, Migraine) and Biomaterial (Metallic, Polymeric, Ceramic) Global Opportunity Analysis and Industry Forecast, 2014 - 2022

Neuromodulation Devices Market by Technology (Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Spinal Cord Stimulation), Application (Chronic Pain Management, Failed back syndrome, Epilepsy, Tremor, Incontinence, Depression, Dystonia, Gastroparesis, Parkinson's disease, Obsessive-Compulsive Disorder, Migraine) and Biomaterial (Metallic, Polymeric, Ceramic) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

Neuromodulation is the alteration of nerve activity by delivering electrical impulses directly to a target area. Neurological disorders such as epilepsy, Alzheimer disease, cerebrovascular diseases, and Parkinson's disease affect the central and peripheral nervous system. Bacterial, viral, and fungal infections can also cause neurological disorders. Growth in the Neuromodulation devices market is attributed to increasing prevalence of neurological disorders due to rapidly rising geriatric population, increasing adoption of neuromodulation devices in developed countries, and growing focus of big players, such as Medtronic and Boston Scientific, on R&D in the segment.

The world neuromodulation devices market is estimated to reach $11,717 million by 2022. The market is expected to be driven by the increasing awareness about the safety and efficacy of neuromodulation devices, rising prevalence of neurological disorders and rising number of clinical trials worldwide for the development of innovative technologies in the field of neuromodulators. However, lack of trained healthcare professionals and stringent approval policies restrain the market growth.
The world neuromodulation devices market is segmented on the basis of product type, technology, application, material and geography. Based on product type, it is categorized into internal and external neuromodulation. Based on technology, Internal neuromodulation is segmented into five major segments, namely, deep brain stimulators, sacral nerve stimulators, spinal cord stimulators, vagus nerve stimulators and other neuromodulation devices. Similarly, based on technology external neuromodulation are classified into transcutaneous electrical nerve stimulation and repetitive transcranial magnetic stimulation. Spinal cord stimulators generated the highest revenue in 2015, whereas the deep brain stimulation market is expected to grow fastest by a CAGR of 13.9%. By application, the market is segmented into the following nine segments: failed back syndrome, chronic pain management, epilepsy, tremors, urinary and fecal incontinence, depression, dystonia, gastroparesis, Parkinson's disease, obsessive-compulsive disorder, migraine, depression and other applications. By biomaterial type, it is divided into metallic biomaterials, ceramic biomaterials and polymeric biomaterials.